Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Selecta Biosciences Awarded Subcontract to Develop a Synthetic Nanoparticle Vaccine for Malaria: Funding Will Be Provided by SAIC through Its Malaria Vaccine Production and Support Services Contract with the National Institute of Allergy and Infectious Diseases (NIAID)

Abstract:
Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that Science Applications International Corporation (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle product for malaria. Funding for the initiative will be provided by SAIC through its Malaria Vaccine Production and Support Services contract with the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health. Selecta's subcontract is part of a collaborative effort by NIAID and the US Agency for International Development (USAID) to jointly develop novel therapeutics and vaccines for malaria and will be funded under SAIC's contract (number N01.AI.05421) with NIAID.

Selecta Biosciences Awarded Subcontract to Develop a Synthetic Nanoparticle Vaccine for Malaria: Funding Will Be Provided by SAIC through Its Malaria Vaccine Production and Support Services Contract with the National Institute of Allergy and Infectious Diseases (NIAID)

Watertown, MA | Posted on August 31st, 2011

"We are extremely pleased that we have been selected to apply our novel vaccine platform to the development of a vaccine for malaria," said Werner Cautreels, Ph.D., President and CEO of Selecta Biosciences. "This collaboration accelerates our progress to apply Selecta's advanced vaccine technology to address the significant unmet medical needs in malaria and highlights the breadth of our vaccine technology to treat a range of diseases that impact human health, including infectious diseases, autoimmune diseases, and smoking cessation."

Under the terms of the award, the targeted Synthetic Vaccine Particle (tSVP™) vaccine for malaria will be developed by Selecta for testing in preclinical studies by SAIC collaborators. tSVP™ products are fully-integrated synthetic nanoparticle vaccines engineered to mimic the properties of natural pathogens to elicit a maximal immune response. Selecta's tSVP™ vaccines are ideally suited to induce a strong immune response to antigens, which has proven to be challenging with other vaccine approaches for certain infectious diseases, such as malaria. Selecta designs tSVP™ products to deliver antigen and adjuvant combinations within the same biodegradable nanoparticle, thus ensuring a focused and durable response while keeping off-target effects at a low level.

####

About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selecta’s fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes. Selecta’s SVP™ platform technology is flexible to enable diverse vaccines and the company has created targeted antigen-specific Synthetic Vaccine Particles (tSVP™) and targeted antigen-specific tolerogenic Synthetic Vaccine Particles (t2SVP™).

Targeted Synthetic Vaccine Particles (tSVP™) activate immune responses to a wide array of relevant antigens, including small molecules, peptides, oligosaccharides, and proteins. These particles can target humoral or cellular pathways of the immune system. Examples for applications include cancer, infectious diseases and addiction. Targeted tolerogenic Synthetic Vaccine Particles (t2SVP™) are designed to induce antigen-specific immune tolerance. Examples for applications include autoimmune diseases, allergies and transplant rejection.

Selecta’s pipeline currently contains a vaccine for smoking cessation and relapse prevention, a vaccine for Type 1 Diabetes, vaccines for several infectious diseases (universal influenza, universal human papillomavirus, and malaria), and research approaches with cancer vaccines and in the field of allergies.

Building on the company’s novel approach, Selecta’s product candidates have the potential to become first-in-class or best-in-class therapeutics to treat and prevent diseases. Selecta Biosciences is based in Watertown, Massachusetts, USA.

For more information, please click here

Contacts:
The Yates Network
Kathryn Morris
845-635-9828

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015

Non-Enzyme Sensor Determines Level of Blood Sugar July 29th, 2015

Flexible Future of Point-of-Care Disease Diagnostic July 29th, 2015

Meet the high-performance single-molecule diode: Major milestone in molecular electronics scored by Berkeley Lab and Columbia University team July 29th, 2015

Govt.-Legislation/Regulation/Funding/Policy

Pakistani Students Who Survived Terror Attack to Attend Weeklong “NanoDiscovery Institute” at SUNY Poly CNSE in Albany July 29th, 2015

Meet the high-performance single-molecule diode: Major milestone in molecular electronics scored by Berkeley Lab and Columbia University team July 29th, 2015

New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015

Short wavelength plasmons observed in nanotubes: Berkeley Lab researchers create Ludinger liquid plasmons in metallic SWNTs July 28th, 2015

Nanomedicine

March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015

Non-Enzyme Sensor Determines Level of Blood Sugar July 29th, 2015

Flexible Future of Point-of-Care Disease Diagnostic July 29th, 2015

Stretching the limits on conducting wires July 25th, 2015

Announcements

Non-Enzyme Sensor Determines Level of Blood Sugar July 29th, 2015

Flexible Future of Point-of-Care Disease Diagnostic July 29th, 2015

Meet the high-performance single-molecule diode: Major milestone in molecular electronics scored by Berkeley Lab and Columbia University team July 29th, 2015

Detecting small metallic contaminants in food via magnetization: A practical metallic-contaminant detecting system using three high-Tc RF superconducting quantum interference devices (SQUIDs) July 29th, 2015

New-Contracts/Sales/Customers

Liquipel Debuts Eyesight-Saving ION-Glass Blue Light Protection for iPhones and Androids at RadioShack Stores Nationwide: Liquipel's Unique Protective Screen, Available at RadioShack, Cuts Harmful Blue Light Implicated in Macular Degeneration by 10x July 28th, 2015

Dais Analytic's Business Affiliate in China Announces Ten-Year Strategic Energy Efficiency Business Arrangement With COFCO: Dais Beijing to Perform Feasibility Study on Over 80 Buildings to Improve Efficiencies as Part of Overall Hotel Energy-Savings Project July 23rd, 2015

Renishaw adds Raman analysis to Scanning Electron Microscopy at the University of Sydney, Australia July 9th, 2015

Oxford Instruments’ TritonXL Cryofree dilution refrigerator selected for the Oxford NQIT Quantum Technology Hub project June 30th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project